Treatment of moderate to severe plaque psoriasis with biologics: Analysis of the additional cost of temporary dose escalation vs switch to another biologic after failure of maintenance therapy;Tratamiento de la psoriasis en placas moderada a grave con fármacos biológicos: análisis del sobrecoste de la intensificación temporal frente a cambio a otro biológico en caso de fracaso secundario

Actas Dermo-Sifiliograficas

Volumn 105, Issue 4, 2014, Pages 401-412

  Puig, L ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Adalimumab; Escalation; Etanercept; Infliximab; Maintenance failure; Psoriasis; Switching; Ustekinumab

Indexed keywords

ADALIMUMAB; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT;

ARTICLE; BODY WEIGHT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; HUMAN; MAINTENANCE THERAPY; PSORIASIS VULGARIS; SINGLE DRUG DOSE; COMPARATIVE STUDY; COST; ECONOMICS; MAINTENANCE CHEMOTHERAPY; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

BIOLOGICAL PRODUCTS; COSTS AND COST ANALYSIS; HUMANS; MAINTENANCE CHEMOTHERAPY; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 84899993956     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.adengl.2013.10.011     Document Type: Article

References (20)

1. L. Puig, J.M. Carrascosa, G. Carretero, P. de la Cueva, R.F. Lafuente-Urrez, and I. Belinchón et al. Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment Actas Dermosifiliogr 104 2013 694 709
2. U. Mrowietz, E.M. de Jong, K. Kragballe, R. Langley, A. Nast, and L. Puig et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis J Eur Acad Dermatol Venereol 2013 10.1111/jdv.12118
3. E.A. Brezinski, and A.W. Armstrong Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy PLoS One 7 2012 e33486
4. C. Leonardi, J.M. Sobell, J.J. Crowley, U. Mrowietz, Y. Bao, and P.M. Mulani et al. Efficacy, safety, and medication cost implications of adalimumab 40 mg weekly dosing in psoriasis patients with sub-optimal response to 40 mg every other week dosing: Results from an open-label study Br J Dermatol 167 2012 658 667
5. K. Reich, C. Griffiths, J. Barker, S. Chimenti, E. Daudén, and A. Giannetti et al. Recommendations for the long-term treatment of psoriasis with infliximab: A dermatology expert group consensus Dermatology 217 2008 268 275
6. R. Langley, M. Lebwohl, G. Krueger, P.O. Szapary, D. Chan, and M. Hsu et al. Long term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 2 long-term extension 21st European Association of Dermatology & Venereology (EADV) congress Prague 27-30 September 2012 Poster 976
7. C. Leonardi, B. Strober, A.B. Gottlieb, B.E. Elewski, J.P. Ortonne, and P. van de Kerkhof et al. Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study J Drugs Dermatol 9 2010 928 937
8. L. Puig Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios Br J Dermatol 168 2013 674 676
9. A. Clemmensen, M. Spon, L. Skov, C. Zachariae, and R. Gniadecki Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris J Eur Acad Dermatol Venereol 25 2011 1037 1040
10. R. Gniadecki, K. Kragballe, T.N. Dam, and L. Skov Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Br J Dermatol 164 2011 1091 1096
11. J. Van den Reek, P.P. van Lümig, W. Kievit, J. Zweegers, P.C. van de Kerkhof, and M. Seyger et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice J Dermatolog Treat 24 2013 361 368
12. B.E. Strober, Y. Poulin, F.A. Kerdel, R.G. Langley, Y. Gu, and S.R. Gupta et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study J Am Acad Dermatol 64 2011 671 681
13. A.B. Gottlieb, R.E. Kalb, A. Blauvelt, M.P. Heffernan, H.L. Sofen, and L.K. Ferris et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study J Am Acad Dermatol 67 2012 642 650
14. C.E. Griffiths, B.E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, N. Yeilding ACCEPT Study Group Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
15. G. Pitarch, J.L. Sánchez-Carazo, L. Mahiques, and V. Oliver Efficacy of etanercept in psoriatic patients previously treated with infliximab Dermatology 216 2008 312 316
16. A. Down Observational case series on a group of patients with severe psoriasis who failed to respond to antitumor necrosis factor a biologics and switched to ustekinumab Br J Dermatol 163 2010 424 437
17. National Institute for Health and Clinical Excellence CG153 Psoriasis: Full guideline [consultado 24 Jun 2013]. Disponible en: http://guidance.nice. org.uk/CG153/Guidance/pdf/English
18. BOT 2.0 (Junio 2013), Consejo General de Colegios Oficiales de Farmacéuticos [consultado 24 Jun 2013]. Disponible en: https://botplusweb.portalfarma.com/
19. Conselleria de Sanitat. Catálogo de procedimientos de enfermería en hospitalización de día. Versión 2002. Catálogos SIE. Valencia: Conselleria de Sanitat, 2003.
20. L. Puig Obesity and psoriasis: Body weight and body mass index influence the response to biological treatment J Eur Acad Dermatol Venereol 25 2011 1007 1011